Delivery Order SPE2DU25D9809-SPE2DU26F0R31

The Defense Logistics Agency (DLA) issued a delivery order valued at $3,483.96 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order, issued on January 16, 2026, falls under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion DLA acquisition strategy designed to consolidate pharmaceutical supply chains across Department of Defense healthcare facilities worldwide. The delivery order represents a firm fixed-price procurement with no set-aside designation, reflecting DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The award is structured as part of DMS Pharmaceutical Group's broader indefinite delivery contract (SPE2DR) with the DLA, which carries a $499,999,999 ceiling and extends through December 31, 2036, positioning the company as a regional prime vendor contractor serving military healthcare operations globally.

DMS Pharmaceutical Group supplies a comprehensive range of pharmaceuticals and medical consumables, including branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and specialty pharmaceuticals to support Department of Defense medical operations. The company has demonstrated substantial federal contracting capability through numerous delivery orders issued by the DLA's Medical Supply Chain division, with no identified subcontractor relationships. The current delivery order continues DMS Pharmaceutical Group's role as a critical supplier within the federal pharmaceutical supply chain, contributing to the DLA's mission to ensure reliable pharmaceutical product availability across the military healthcare system.